Detailed description page of ThPDB2

This page displays user query in tabular form.

10797 details
Primary information
ID10797
Therapeutic IDTh1186
Protein NameHuman rabies virus immune globulin
SequenceNA
Molecular WeightNA
Chemical FormulaNA
Isoelectric PointNA
HydrophobicityNA
Melting pointNA
Half-lifeNA
DescriptionNA
Indication/DiseaseIt is indicated for individuals suspected of exposure to rabies, particularly severe exposure, with one exception: persons who have been previously immunized with HDCV Rabies Vaccine in a pre-exposure or postexposure treatment series should receive only vaccine.
PharmacodynamicsNA
Mechanism of ActionIt provides passive protection by neutralizing the rabies virus when given to individuals exposed to rabies virus. When a rabies immune globulin dose of 20 IU/kg was given simultaneously with the first dose of rabies vaccine, levels of passive anti-rabies antibody were detected 24 hours after injection in all individuals. There was minimal or no interference with the immune response to the initial and subsequent doses of rabies vaccine, including booster doses.
ToxicityNA
MetabolismNA
AbsorptionNA
NA
ClearanceNA
CategoriesNA
Patents NumberNA
Date of IssueNA
Date of ExpiryNA
Drug InteractionLive virus vaccines, such as measles vaccine, should not be given for four months following Human rabies virus immune globulin administration because antibodies in the immune globulin preparation may interfere with the immune response to the vaccine.
TargetNA
Brand NameHyperrab S/d
CompanyGrifols Therapeutics Inc
Brand DescriptionGrifols Therapeutics Inc
Prescribed ForRabies immune globulin is used together with rabies vaccine to prevent infection caused by the rabies virus.
Chemical NameNA
Formulation150 unit
Physical Appearance Solution
Route of Administrationintramuscular
Recommended DosageThe recommended dose for HyperRAB S/D is 20 IU/kg (0.133 mL/kg) of body weight given preferably at the time of the first vaccine dose
ContraindicationHypersensitivity
Side EffectsFever, pain, soreness, tenderness, or stiffness at the injection site, Skin rash
Useful Link 1Link
Useful Link 2NA
RemarksNA